tiprankstipranks
Trending News
More News >
Imunon (IMNN)
NASDAQ:IMNN

Imunon (IMNN) AI Stock Analysis

Compare
1,306 Followers

Top Page

IM

Imunon

(NASDAQ:IMNN)

Rating:41Neutral
Price Target:
Imunon's financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock's risky profile, with a negative P/E ratio and no dividend yield.
Positive Factors
Operational Strategy
Imunon's cost-effective approach, including in-house manufacturing and competitive pricing, has allowed it to beat internal cost projections for the trial.
Regulatory Advantage
IMNN-001 has orphan status in the US and EU, providing regulatory benefits and market exclusivity.
Therapy Efficacy
IMNN-001 therapy led to consistent and clinically meaningful improvements in key endpoints across treatment groups, including a 13-month increase in overall survival and a 3-month increase in progression-free survival compared to standard care.
Negative Factors
Capital Needs
Imunon has secured near-term financing through a private placement, providing essential capital needed to cover initiation-related costs of the OVATION study.
Financial Uncertainty
The company is in active discussions with potential partners to secure essential capital for the Phase 3 OVATION 3 study.

Imunon (IMNN) vs. SPDR S&P 500 ETF (SPY)

Imunon Business Overview & Revenue Model

Company DescriptionImunon, Inc. (IMNN) is a biotechnology company focused on the development and commercialization of innovative therapies that leverage its proprietary platform technologies. The company's primary areas of focus include oncology and infectious diseases, with a core emphasis on developing advanced DNA-based immunotherapies and vaccine solutions. Imunon aims to address unmet medical needs by providing effective and safe treatment options for patients worldwide.
How the Company Makes MoneyImunon generates revenue primarily through the development and commercialization of its proprietary therapeutic and vaccine solutions. The company may engage in licensing agreements, where it partners with other pharmaceutical or biotechnology firms to co-develop or distribute its products, thereby earning licensing fees and royalties. Additionally, Imunon may receive funding from government grants or research collaborations, which contribute to its research and development efforts. By advancing its pipeline of candidates through clinical trials and achieving regulatory approvals, Imunon positions itself to earn revenue from product sales, either directly or through strategic partnerships.

Imunon Earnings Call Summary

Earnings Call Date:May 12, 2025
(Q1-2025)
|
% Change Since: 0.00%|
Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in clinical trials and positive reception from the medical community, but financial constraints and increased expenses remain challenges. The company's strategic focus on securing partnerships and financing is crucial for advancing their objectives.
Q1-2025 Updates
Positive Updates
Initiation of Phase III OVATION 3 Trial
Imunon initiated the first clinical site for their Phase III pivotal study of Imunon-001 for ovarian cancer. The trial is recognized by the medical community and has received acceptance for presentations at major conferences.
Positive Reception from Medical Community
The OVATION 3 trial has been met with enthusiasm from leading hospitals and international investigators, many of whom participated in earlier phases of the study.
Financial Management and Strategy
Imunon is focused on securing value-added financing and partnerships to support their clinical timelines and strategic objectives, emphasizing cost-effective strategies and partnerships.
Oral Presentation at ASCO Annual Meeting
Imunon's OVATION 2 trial results were accepted for an oral presentation at the ASCO Annual Meeting, highlighting the significance of their research in the medical community.
Negative Updates
Financial Constraints and Cash Runway
As of March 31, 2025, Imunon had $2.9 million in cash, with a need for near-term financing to strengthen financial conditions and advance the OVATION 3 trial.
Increased General and Administrative Expenses
Imunon's general and administrative expenses increased to $2 million in Q1 2025 from $1.7 million in Q1 2024, primarily due to higher employee-related expenses.
Net Loss for Q1 2025
Imunon reported a net loss of $4.1 million or $0.28 per share for Q1 2025, compared to a net loss of $4.9 million or $0.52 per share in the same period of 2024.
Company Guidance
During the Imunon first quarter 2025 financial results call, the company provided significant guidance on its Phase III OVATION 3 trial for IMNN-001, aimed at treating advanced ovarian cancer. The study, which has initiated its first clinical site, will include 500 patients in an all-comers population, with a focus on a 250-patient subgroup identified by a biomarker for homologous recombination deficiency (HRD). Primary and secondary endpoints include overall survival (OS), surgical response, and time to second-line treatment, with exploratory endpoints assessing quality of life to aid in future payer discussions. The trial is expected to cost 40% less by initially focusing on the HRD subgroup and could yield results two years earlier. Imunon also highlighted its financial status, with $2.9 million in cash as of March 31, 2025, and ongoing efforts to secure financing and partnerships to support its clinical milestones. The company is actively pursuing corporate partnerships, particularly in oncology and vaccine development, to cover the OVATION 3 trial costs, while emphasizing the potential of its PlaCCine vaccine technology.

Imunon Financial Statement Overview

Summary
Imunon faces significant financial challenges, as indicated by consistently negative revenue, profitability, and cash flow metrics. High leverage and negative returns further exacerbate financial instability. The company needs strategic financial restructuring and improved operational performance to enhance its financial health and investor confidence.
Income Statement
10
Very Negative
Imunon has consistently reported zero or negative revenue over the past years. Gross profit margins are nonexistent, with significant net losses indicating severe profitability issues. EBIT and EBITDA margins are deeply negative, showing a lack of operational efficiency. There is no evidence of revenue growth, suggesting challenges in achieving market penetration or product commercialization.
Balance Sheet
25
Negative
The company exhibits a relatively high debt-to-equity ratio, indicating reliance on debt financing. Return on Equity (ROE) is negative, reflecting ongoing net losses. The equity ratio shows some equity presence but is overshadowed by continuous financial strain. The balance sheet stability is questionable due to high leverage and negative equity returns.
Cash Flow
20
Very Negative
Operating cash flow is consistently negative, reflecting poor cash generation from operations. Free cash flow is also negative, indicating insufficient cash to cover capital expenditures. Despite some positive financing and investing cash flow activities, the company's overall cash flow position is weak, raising concerns about liquidity and future operational funding.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.00500.00K500.00K500.00K
Gross Profit0.000.000.00500.00K500.00K500.00K
EBITDA-17.10M-17.98M-19.88M-31.71M-20.88M-21.30M
Net Income-17.79M-18.62M-19.51M-35.90M-20.77M-21.48M
Balance Sheet
Total Assets6.86M9.72M21.92M43.98M74.05M37.53M
Cash, Cash Equivalents and Short-Term Investments2.87M5.87M15.70M32.75M49.39M17.16M
Total Debt1.01M1.14M1.62M6.27M6.63M6.19M
Total Liabilities6.41M5.47M8.53M14.65M18.25M18.92M
Stockholders Equity452.03K4.24M13.39M29.33M55.80M18.61M
Cash Flow
Free Cash Flow-16.11M-18.88M-19.47M-23.36M-16.54M-15.64M
Operating Cash Flow-15.83M-18.85M-19.02M-23.10M-16.22M-15.62M
Investing Cash Flow7.19M9.83M11.01M8.28M-30.12M7.92M
Financing Cash Flow9.17M9.06M-3.64M6.72M54.77M17.98M

Imunon Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.80
Price Trends
50DMA
1.08
Negative
100DMA
0.99
Negative
200DMA
0.95
Negative
Market Momentum
MACD
-0.13
Positive
RSI
41.13
Neutral
STOCH
25.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNN, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 1.15, below the 50-day MA of 1.08, and below the 200-day MA of 0.95, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 41.13 is Neutral, neither overbought nor oversold. The STOCH value of 25.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMNN.

Imunon Risk Analysis

Imunon disclosed 1 risk factors in its most recent earnings report. Imunon reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Imunon Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$15.31B5.72-7.43%4.61%11.60%-21.06%
48
Neutral
$11.93M-117.16%175.03%55.34%
42
Neutral
$11.90M-76.12%81.71%
41
Neutral
$16.26M-397.54%24.16%
41
Neutral
$15.99M-89.73%-100.00%-292.59%
40
Underperform
$15.36M-106.05%9.46%
34
Underperform
$7.13M-174.66%38.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMNN
Imunon
0.80
-0.56
-41.18%
MEIP
MEI Pharma
2.40
-0.40
-14.29%
PHIO
Phio Pharmaceuticals
2.48
-2.76
-52.67%
COCP
Cocrystal Pharma
1.51
-0.87
-36.55%
BRTX
BioRestorative Therapies
1.59
-0.28
-14.97%
INAB
IN8bio
2.16
-21.84
-91.00%

Imunon Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Imunon Appoints Dr. Douglas Faller as CMO
Positive
Feb 10, 2025

On February 18, 2025, IMUNON appointed Dr. Douglas Faller as Chief Medical Officer to lead the company’s clinical strategy, including advancing its lead program IMNN-001 into a Phase 3 trial for advanced ovarian cancer. Dr. Faller brings over 30 years of experience in oncology and immunology, and his appointment is expected to bolster IMUNON’s efforts in progressing its pipeline of non-viral DNA-based immunotherapies, leveraging his expertise to drive clinical programs and potential commercialization.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025